MedTrace Logo

A Trial Investigating the Absolute Bioavailability of Insulin Degludec in Healthy Subjects

NCT01623375 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2015-02-19

No results posted yet for this study

Summary

This trial is conducted in Europe. The aim of the trial is to investigate the absolute bioavailability of insulin degludec (IDeg) in healthy subjects.

Conditions

Interventions

DRUG

insulin degludec

A single dose of 0.4 U/kg body weight will be administered subcutaneously (s.c., under the skin).

DRUG

insulin degludec

A single dose of 0.04 U/kg body weight will be administered intravenously (i.v., into the vein).

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01623375 on ClinicalTrials.gov